Market Size of Global Amyotrophic Lateral Sclerosis Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.30 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis
The amyotrophic lateral sclerosis treatment market is expected to register a CAGR of 6.3% during the forecast period (2022-2027).
COVID-19 had a significant impact on the studied market as it affected not only diagnostic and treatment procedures but also research and development activities in the area. For instance, in June 2020, the World Health Organization issued the results of a survey conducted in 155 countries for three weeks in May 2020, which showed that the prevention and treatment services of various chronic diseases, including various neurodegenerative disorders, had been severely disrupted, and this has become a significant concern because people living with chronic disorders were at higher risk of severe COVID-19-related illness and death. Therefore, COVID-19 harmed the studied market.
In addition, the rising prevalence of amyotrophic lateral sclerosis and the growing geriatric population are actively affecting the growth of the studied market.
According to the United Nations World Population Prospects 2022 report, there are 77.1 million people aged 65 years or over living in the world in 2022, and this number is projected to reach 1.6 billion by the year 2050. This surge in the geriatric population is expected to increase the burden of rare neurological diseases which is likely to augment the growth of the studied market over the forecast period.
Furthermore, the article titled "Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants" published in Neuroepidemiology Journal in July 2021 stated that combined prevalence rates (per 100,000 people) and incidence rates (per 100,000 person-years) were 6.22 and 2.31 for Europe, 5.20 and 2.35 for North America, 3.41 and 1.25 for Latin America, 3.01 and 0.93 for Asian countries excluding Japan, and 7.96 and 1.76 for Japan, respectively. The increase in prevalence and incidence of the disease is expected to increase the demand for the treatment and thus boost the market growth.
The advancements and increasing product approvals, along with partnerships and collaborations by key players are helping in the market growth. For instance, in June 2021, CRISPR Therapeutics and CapsidaBiotherapeutics Inc. entered into a strategic partnership to research, develop, manufacture and commercialize in vivo gene editing therapies using CRISPR technology delivered with engineered AAV vectors for the treatment of familial amyotrophic lateral sclerosis (ALS) and Friedreich's ataxia. Such partnerships are likely to bolster market growth.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, the high cost of treatment is likely to impede market growth.
Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Segmentation
As per the scope of the report, amyotrophic lateral sclerosis (ALS) is a neurological disorder and fatal disease that affects nerve cells in the neuron and spinal control which controls voluntary muscle movement in the human body. This disorder affects neurons which results in blockage of messages between muscles and the brain. The amyotrophic lateral sclerosis treatment market is segmented by Treatment Type (Medication and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Treatment Type | |
| Medication | |
| Others |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Amyotrophic Lateral Sclerosis Treatment Market Size Summary
The amyotrophic lateral sclerosis (ALS) treatment market is poised for growth, driven by the increasing prevalence of the disease and the expanding geriatric population. The market has faced challenges due to the COVID-19 pandemic, which disrupted diagnostic and treatment procedures, as well as research and development activities. However, the rising incidence of ALS and the aging population are expected to bolster market expansion. The market is characterized by advancements in treatment options, including gene editing therapies and strategic partnerships among key players, which are anticipated to enhance market dynamics. Despite the high cost of treatment posing a potential barrier, the demand for medications like riluzole and edaravone, approved by the FDA, is expected to grow, supporting the market's upward trajectory.
North America is projected to lead the ALS treatment market, attributed to the region's robust healthcare infrastructure, heightened awareness, and a strong presence of industry players. The increasing incidence of rare neurological diseases and the aging population further contribute to the region's market dominance. Government initiatives, such as the FDA's action plan for rare neurodegenerative diseases, aim to advance research and improve patient access to novel treatments, thereby fostering market growth. The competitive landscape is moderately fragmented, with several global and regional companies, including Mitsubishi Tanabe Pharma Corporation and Amylyx Pharmaceuticals Inc., actively participating in the market. Recent drug approvals in Canada and the United States underscore the ongoing efforts to address ALS, reinforcing the market's potential for continued expansion.
Global Amyotrophic Lateral Sclerosis Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Prevalence of Amyotrophic Lateral Sclerosis
-
1.2.2 Growing Geriatric Population
-
-
1.3 Market Restraints
-
1.3.1 High Cost of Treatment
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Treatment Type
-
2.1.1 Medication
-
2.1.2 Others
-
-
2.2 By Distribution Channel
-
2.2.1 Hospital Pharmacies
-
2.2.2 Retail Pharmacies
-
2.2.3 Others
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Amyotrophic Lateral Sclerosis Treatment Market Size FAQs
What is the current Global Amyotrophic Lateral Sclerosis Treatment Market size?
The Global Amyotrophic Lateral Sclerosis Treatment Market is projected to register a CAGR of 6.30% during the forecast period (2024-2029)
Who are the key players in Global Amyotrophic Lateral Sclerosis Treatment Market?
Mitsubishi Tanabe Pharma Corporation, CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc. and Biogen are the major companies operating in the Global Amyotrophic Lateral Sclerosis Treatment Market.
